About us
GAP-f is a WHO Network hosted within the Research for Health Department in the Science Division and was created to respond to the paediatric treatment gap.
Following the resolution at the 69th World Health Assembly on promoting innovation and access to quality, safe, efficacious and affordable medicines for children, GAP-f was conceived to build on and formalize the model developed within the HIV community to provide a sustainable mechanism that ensures that safer, more effective, and more durable paediatric formulations are developed and made available to children against an accelerated timeline.
At GAP-f, Children are at the top of our agenda. While there have been significant achievements in child health with six million fewer children under the age of five years dying in 2016 than in 1990, urgent action is needed to achieve the UN Sustainable Development Goals (SDG), particularly SDG 3, which aims to ensure healthy lives and promote wellbeing for all people at all ages and the related target to achieve Universal Health Coverage by 2030.
GAP-f would like to thank Digital Medic and its partners for supporting this video.
Documents
All →
Publications
All →Paediatric drug optimization (PADO) exercises aim to identify key priority products and their preferred product characteristics for research and development....
Cefiderocol was included in WHO’s PADO priority list because of its efficacy against multiple pathogens in the WHO bacterial priority pathogens list,...
This report provides an overview of the funding and R&D landscape in childhood cancer. The report, based on data from the WHO Global Observatory on...
In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets,...
Articles
Newsletter
Subscribe to our newsletter and other updates here.
Events
All →GAP-f Secretariat
Contact
For more information email: [email protected]